Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living with HIV on Suppressive Antiretroviral Therapy
Active Not Recruiting
Trimer 4571 is a vaccine designed to stimulate the development of broadly neutralizing antibodies (bnAbs) against HIV. Trimer 4571 is investigational, meaning it is not approved by the US Food and Drug Administration (FDA). There is limited human experience with the Trimer 4571 vaccine administered with aluminum hydroxide (alum) and the vaccine has not been tested in people with HIV prior to this study although it has been tested in healthy volunteers. The goal of this study is to see if Trimer... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: HIV Infections
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
Recruiting
The purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to \<65 years of age.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/19/2025
Locations: DM Clinical Research - Philadelphia, Philadelphia, Pennsylvania
Conditions: Influenza, SARS-CoV-2
A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults
Completed
This is an open-label, dose-escalation study to examine the safety, tolerability, and immunogenicity of adjuvanted Fusion Peptide Vaccine alone or in prime-boost regimens with adjuvanted Trimer 4571 and Trimer 6931 vaccines in healthy adults. The hypothesis is that the vaccines will be safe, and well tolerated when administered alone, and when co-administered with HIV-1 Trimer 4571, in prime-boost regimens, and will induce detectable immune response.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
03/17/2025
Locations: University of Pittsburgh CRS [1001], Pittsburgh, Pennsylvania
Conditions: HIV
A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults
Not Yet Recruiting
This purpose of this phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/17/2025
Locations: DM Clinical Research - Philadelphia, Philadelphia, Pennsylvania
Conditions: Respiratory Syncytial Virus (RSV)
A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
Recruiting
The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together. This study is seeking healthy participants aged 18 or older. All participants in this study will receive only 1 shot to their arm, either a flu or COVID vaccine, alone or mixed. Participants will take part in this study for about 6 months, and participants will need to visit the clinical study site at least 4 times.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: DM Clinical Research - Philadelphia, Philadelphia, Pennsylvania
Conditions: Influenza, COVID-19 (Coronavirus Disease 2019)
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
Active Not Recruiting
This phase I trial studies the side effects and best dose of deoxyribonucleic acid (DNA) vaccine therapy in treating patients with hepatitis C virus (HCV) infection that persists or progresses over a long period of time. Vaccines made from DNA may help the body build an effective immune response to kill cancer cells that express HCV infection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Temple University Hospital, Philadelphia, Pennsylvania
Conditions: Chronic Hepatitis, Hepatitis C Infection, Hepatocellular Carcinoma
Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older
Completed
The primary objectives of the study are: To assess the safety profile of the study vaccines in each study intervention group. To assess the neutralizing antibody profile after primary series vaccination in SARS-CoV-2-naïve adults. To demonstrate that a booster dose of monovalent or bivalent SARS-CoV-2 vaccine given to adults previously vaccinated with an authorized/approved COVID-19 vaccine induces an immune response that is non-inferior to the response induced by a twodose priming series wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: University of Pittsburgh Site Number : 8400233, Pittsburgh, Pennsylvania
Conditions: COVID-19
A Study About Modified RNA Vaccines Against Influenza in Healthy Adults
Completed
The purpose of this study is to learn if modified RNA (modRNA) vaccines for the prevention of influenza are: * safe; and * how these vaccines produce an immune response in generally healthy adults. Immune response is the way the body protects itself against things it sees as harmful or foreign. RNA (also called ribonucleic acid) is one of two types of nucleic acid made by cells. RNA contains information that has been copied from DNA (the other type of nucleic acid). Cells make several differen... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: DM Clinical Research - Philadelphia, Philadelphia, Pennsylvania
Conditions: Influenza, Human
Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age
Completed
The purpose of this study is to evaluate the immunogenicity, safety and tolerability of rMenB+OMV NZ and MenACWY vaccines when concomitantly administered to healthy subjects 16-18 years of age.
Gender:
ALL
Ages:
Between 16 years and 18 years
Trial Updated:
02/11/2025
Locations: GSK Investigational Site, Erie, Pennsylvania +5 locations
Conditions: Infections, Meningococcal
A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age
Completed
The purpose of this study is to assess immune response and safety of various potencies of an investigational chickenpox vaccine given to healthy children 12 to 15 months of age.
Gender:
ALL
Ages:
Between 12 months and 15 months
Trial Updated:
02/07/2025
Locations: GSK Investigational Site, Fort Washington, Pennsylvania
Conditions: Chickenpox
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
Completed
The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus nonconcomitant administration of 9vHPV and mRNA-1273 vaccines in boys and girls 9 to 11 years of age.
Gender:
ALL
Ages:
Between 9 years and 11 years
Trial Updated:
02/04/2025
Locations: Thomas Jefferson University - Family and Community Medicine ( Site 0006), Philadelphia, Pennsylvania
Conditions: Papillomavirus Infections, Coronavirus Disease (COVID-19)
A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults
Completed
The purpose of this study is to measure the safety and the immune response to 3 next-generation influenza vaccine candidates (mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1) compared with influenza vaccine candidate mRNA-1010 controls in healthy adult participants.
Gender:
ALL
Ages:
Between 50 years and 75 years
Trial Updated:
01/28/2025
Locations: Hatboro Medical Associates / CCT Research, Hatboro, Pennsylvania
Conditions: Seasonal Influenza